CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for ARYx Therapeutics, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

ARYx Therapeutics, Inc.
6300 Dumbarton Cir
Phone: (510) 585-2200p:510 585-2200 FREMONT, CA  94555-3644  United States Ticker: ARYXARYX

This company ceased filing statements with the SEC on 4/8/2011.

Business Summary
ARYx Therapeutics, Inc. is a United States-based pharmaceutical Company. The Company is developing a proprietary portfolio of patient-targeted, first-in-class monoclonal antibodies designed to treat seriously ill patients with difficult-to-treat diseases. It is engaged in retrometabolic drug design that focuses on the safety of oral therapies for chronic disease. The Companys clinical compounds include naronapride (ATI-7505) for gastrointestinal disorders; budiodarone (ATI-2042, for the treatment of atrial fibrillation; tecarfarin (ATI-5923) for the treatment of anticoagulation; and ATI-9242, for psychiatric disorders.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/201012/31/2009YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, Chief Executive Officer PaulGoddard 68 4/1/2005 8/1/2003
Chief Operating Officer John W.Varian 61 3/10/2011 12/1/2003
Vice President - Corporate Affairs, Secretary DavidNagler 67 7/1/2003 7/1/2003
Director Nicholas J.Simon 64 6/1/2002 6/1/2002

Business Names
Business Name
ARYX
ARYx Therapeutics Inc.
ARYx Therapeutics Limited

General Information
Number of Employees: 56 (As of 12/31/2009)
Outstanding Shares: 33,461,975 (As of 9/30/2010)
Shareholders: 84
Stock Exchange: OTC
Federal Tax Id: 770456039
Fax Number: (510) 585-2202
Email Address: info@aryx.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, August 30, 2023